LOGIN  |  REGISTER
Chimerix

Personalis to Participate at Upcoming Investor Conferences

November 20, 2024 | Last Trade: US$6.01 0.06 1.01

FREMONT, Calif. / Nov 20, 2024 / Business Wire / Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, announced today that its management team will participate at the following investor conferences:

  • Piper Sandler 36th Annual Healthcare Conference
    Date: Tuesday, December 3, 2024
    Fireside Chat Time: 12:30 pm Eastern Time
    Location: The Lotte New York Palace in New York, NY
  • TD Cowen Diagnosing Tomorrow: Tools & Technologies for the Next Decade
    Date: Thursday, December 12, 2024
    Panel Topic: MRD - The Future Tech Stack
    Panel Time: 1:30 pm Eastern Time
    Location:
    One Vanderbilt in New York, NY

About Personalis, Inc.

At Personalis, we are transforming the active management of cancer through breakthrough personalized testing. We aim to drive a new paradigm for cancer management, guiding care from biopsy through the life of the patient. Our highly sensitive assays combine tumor-and-normal profiling with proprietary algorithms to deliver advanced insights even as cancer evolves over time. Our products are designed to detect minimal residual disease (MRD) and recurrence at the earliest timepoints, enable the selection of targeted therapies based on ultra-comprehensive genomic profiling, and enhance biomarker strategy for drug development. Personalis is based in Fremont, California. To learn more, visit www.personalis.com and connect with us on LinkedIn and X (Twitter).

Recursion

Stock Quote

Featured Stock

Terns Pharmaceuticals

Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...

CLICK TO LEARN MORE

Featured Stock

Astria Therapeutics

Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page

COPYRIGHT ©2023 HEALTH STOCKS HUB